

Applicants: Bruce D. Gaynor et al.

Appln No.: 08/833,838

Filed: April 10, 1997

page 2 of 5

Amendments to the Claims

Please cancel claim 75 without disclaimer or prejudice to applicants' right to pursue the subject matter of this claim in a future continuation or divisional application. Please amend claim 54 as set forth below.

1-53. (Canceled)

54. (Currently amended) A method of treating a subject having glomerulonephritis, inhibiting binding of an anti-double standard (ds) DNA antibody to glomeruli of renal tissue in a subject, wherein the anti-ds DNA antibody binds to the same epitope as an R4A antibody, the method comprising administering to said subject at least one peptide ~~in an amount effective to~~ that binds to an anti-double stranded-ds-DNA antibody in the subject, wherein said peptide comprises a D-amino acid sequence of X1-Trp-X1-Tyr-X2, wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

55. (Previously presented) The method according to Claim 54 wherein said peptide is 5-30 D-amino acids in length.

56. (Previously presented) The method according to Claim 54 wherein said peptide is 5-15 D-amino acids in length.

57. (Previously presented) The method according to Claim 54 wherein said peptide is 5-10 D-amino acids in length.

58. (Previously presented) The method according to Claim 54 wherein said peptide is 5 D-amino acids in length.

59-70. (Canceled)

Applicants: Bruce D. Gaynor et al.

Appln No.: 08/833,838

Filed: April 10, 1997

page 3 of 5

71. (Previously presented) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser.

72. (Previously presented) The method according to Claim 71 wherein said peptide is 5-15 amino acids in length.

73. (Previously presented) The method according to Claim 71 wherein said peptide is 5-10 amino acids in length.

74. (Previously presented) The method according to Claim 71 wherein said peptide consists of d-Asp-Trp-Glu-Tyr-Ser.

75. (Canceled)